High-Dose Thiamine Supplementation in Older Patients With Heart Failure: A Pilot Randomized Controlled Crossover Trial (THIAMINE-HF)

Eric K.C. Wong, MD, Justin Y. Lee, BScPhm, MD, PhD, Justin Chow, MD, Patricia Power, BSc, MSc, Laura Jin, BSc, MSc, Darryl P. Leong, MBBS, MPH, M.Biostat, PhD, Lawrence Mbuagbaw, MD, MPH, PhD, Sabina Keen, MD, Haroon Yousuf, MD, MHSc, Christopher Patterson, MD, Sharon Straus, MD, MSc, and Catherine Demers, MD, MSc

ABSTRACT

Background: Thiamine supplementation may improve cardiac function in older adults with heart failure (HF). Our objectives were to determine the following: (i) the feasibility of conducting a large trial of thiamine supplementation in HF; and (ii) the effects of thiamine on clinical outcomes.

Methods: We conducted a double-blinded randomized placebo-controlled 2-period crossover feasibility study from June 2018 to April 2021. Adults aged ≥ 60 years with symptomatic HF and reduced left ventricular ejection fraction (LVEF) with thiamine doses of 200-300 mg/d.6 Another trial of 50 stable HFrEF patients (mean age: 61.4 years) found no changes in LVEF or N-terminal pro-brain natriuretic peptide (NT-proBNP) level after 6 months of thiamine supplementation (200 mg/d).8

Thiamine (vitamin B1) is an essential micronutrient that is required for energy production in the heart. Even though thiamine is an essential cofactor for 2 enzymatic steps in adenosine triphosphate synthesis, it is not synthesized in the body. If a diet is thiamine-deficient, the body will deplete its store in 2-3 weeks.1 Thiamine deficiency is common in patients with heart failure (HF), occurring in 33% of patients.2 The failing heart exhibits decreased adenosine triphosphate levels when examined using magnetic resonance spectroscopy.3 Patients with heart failure with reduced ejection fraction (HFrEF),3 older age,4 or diuretic use5 are more likely to have thiamine deficiency.

Small, randomized trials have shown inconsistent benefits of thiamine supplementation in HF. A meta-analysis of 2 small placebo-controlled trials (pooled n = 38) showed a small improvement (absolute increase of 3.28%, 95% confidence interval [CI] 0.64-5.93) in left ventricular ejection fraction (LVEF) with thiamine doses of 200-300 mg/d.7 Another trial of 50 stable HFrEF patients (mean age: 61.4 years) showed no change to LVEF after 1 month of thiamine supplementation (300 mg/d), but there was an improvement in patient-reported peripheral edema. A recent trial of 69 stable HFrEF patients (mean age: 56.7 years) found no changes in LVEF or N-terminal pro-brain natriuretic peptide (NT-proBNP) level after 6 months of thiamine supplementation (200 mg/d).8

One reason for the inconsistent results in the literature may be related to the age of participants. Older adults aged ≥ 65...
ejection fraction (≤ 45%) were included. Participants were randomized to thiamine mononitrate 500 mg, or placebo, for 90 days and were switched to the opposite treatment for 90 days after a 6-week washout period. The primary feasibility outcome was recruitment of 24 participants in 11 months.

Results: We screened 330 patients over 21 months to recruit 24 patients. Participants' mean age was 73.4 years. The targets for refusal rate, retention rate, and adherence rate were met. Nonsignificant improvements occurred in left ventricular ejection fraction and N-terminal pro-brain natriuretic peptide (NT-proBNP) level with thiamine. A total of 13 serious adverse events occurred in 7 patients; none were related to the study drug.

Conclusions: Although we did not reach our recruitment target, we found high-dose thiamine supplementation to be well tolerated, with potential improvements in biomarker outcomes. A larger trial of thiamine supplementation is warranted.

Materials and Methods

Study design, population, and setting

We conducted a randomized placebo-controlled 2-period crossover feasibility study of thiamine supplementation in HF. The study was conducted from June 2018 to April 2021 in Hamilton, Canada. The protocol and rationale for this study have been published elsewhere. Briefly, we included adults age ≥ 60 years with symptomatic HF (New York Heart Association [NYHA] class II-IV), LVEF ≤ 45%, and either of the following: (i) a HF-related hospitalization in the past 12 months; or (ii) an NT-proBNP level > 600 ng/L within 60 days of screening. Due to challenges with recruiting stable patients with recent HF-related hospitalization, we added the option of using NT-proBNP level as an alternative to requiring a recent hospitalization, similar to the approach used in other recent HF trials. Patients also were optimized medically on guideline-directed medical therapy and were stable on medications without hospitalization in the month immediately preceding enrollment. Exclusion criteria included taking > 2.5 mg/d of a thiamine supplement (typical content in a multivitamin tablet), having end-stage renal disease on dialysis, having severe mitral valve disease (which affects strain echocardiography interpretation), having cognitive impairment (defined by chart documentation) without a caregiver administering medications, or having an expected survival period of < 1 year due to noncardiac disease. Patients with symptomatic thiamine deficiency (Wernicke’s encephalopathy, severe malnutrition, or refeeding syndrome) or heavy alcohol use (> 15 drinks per day in men and ≥ 10 drinks per day in women) also were excluded. A full list of eligibility criteria is available in the protocol. We followed the Consolidated Standards of Reporting Trials (CONSORT) statement adapted for crossover trials.

Conclusions: Bien que nous n’ayons pas atteint notre cible de recrutement, nous avons observé que la supplémentation en thiamine à dose élevée était bien tolérée et qu’il y avait des améliorations potentielles des résultats des biomarqueurs. Un essai de plus grande envergure sur la supplémentation en thiamine est justifié.

Procedures

Patients were recruited from the Heart Function Clinic at the Hamilton General Hospital (Hamilton, Ontario, Canada) by a research assistant. Eligible participants provided written consent for the study. Participants were then randomly assigned to start with either thiamine mononitrate 500 mg orally each day, or placebo, in a blinded fashion. The bottles of study drug and placebo were pre-randomized and sequentially labelled by the manufacturer using a randomization assignment list to which only the statistician and pharmacy had access. Study investigators were blinded to the assignments. Each participant took the study medication (thiamine or placebo) for 90 days (phase 1), which was followed by a 6-week washout period. Participants then switched to the other study medication (placebo or thiamine) for 90 days (phase 2). Each participant had a total of 4 study visits, occurring at the start and end of each medication phase. Each study visit included a medication questionnaire, and a review for adverse events and hospital visits. A pre-planned external review by a cardiologist was done midway through the study to assess for safety concerns. The external reviewer was not blinded to drug allocation, but the investigators remained blinded.

Outcomes

The primary outcome of the study was the feasibility of recruiting 24 participants in 11 months. Secondary outcomes...
included additional feasibility outcomes and exploratory clinical outcomes. Secondary feasibility outcomes included refusal rate (defined as number of eligible patients who refused to participate; feasibility threshold < 40%), retention rate (defined as number of enrolled patients completing the study; feasibility threshold > 80%), and adherence rate (a patient was considered adherent when they took at least 80% of the study drug; feasibility threshold > 90% of participants being adherent to the drug). We also measured TPP level at each visit, to detect biochemical evidence of supplementation.

Secondary clinical outcomes included echocardiographic measurements (peak global longitudinal strain [GLS] and LVEF), NYHA functional class, NT-proBNP level, quality-of-life questionnaire score (the Kansas City Cardiomyopathy Questionnaire [KCCQ]), and clinical events. Clinical events included all-cause mortality, HF hospitalizations, HF emergency room visits, and other adverse events.

**Sample size and statistical analysis**
A sample size of 24 patients (12 per arm) was determined to be sufficiently large to inform feasibility outcomes and to gather estimates of precision of clinical outcomes. The feasibility outcomes were analyzed by comparing estimates to predefined thresholds. Changes in clinical outcomes were tested using analysis of variance (ANOVA) models accounting for period and carryover effects. Mean differences, 95% confidence intervals, and P values are reported. The level of significance was set at α = 0.05. We conducted a secondary analysis using a linear mixed-effects model adjusting for baseline values and

| Baseline characteristics of enrolled patients (n = 24). |
|-----------------|------------------|------------------|
| Variables       | Thiamine, then placebo (n = 12) | Placebo, then thiamine (n = 12) | Total (n = 24) |
| Age, y          | 72.6 (± 7.0)      | 74.1 (± 8.0)      | 73.4 (± 7.4)   |
| Sex, female     | 5 (41.7)          | 2 (16.7)          | 7 (29.2)       |
| NYHA class      |                   |                   |                |
| 1               | 0 (0.0)           | 0 (0.0)           | 0 (0.0)        |
| 2               | 9 (75.0)          | 9 (75.0)          | 18 (75.0)      |
| 3               | 3 (25.0)          | 3 (25.0)          | 6 (25.0)       |
| 4               | 0 (0.0)           | 0 (0.0)           | 0 (0.0)        |
| Hospitalizations in past 12 months | 5 (41.7) | 7 (58.3) | 12 (50.0) |
| Emergency room visits in past 12 months | 2 (16.7) | 6 (50.0) | 8 (33.3) |
| Ischaemic heart failure | 9 (75.0) | 7 (58.3) | 16 (66.7) |
| Comorbidities   |                   |                   |                |
| Diabetes        | 5 (41.7)          | 4 (33.3)          | 9 (37.5)       |
| Hypertension    | 6 (50.0)          | 9 (75.0)          | 15 (62.5)      |
| Dyslipidemia    | 5 (41.7)          | 7 (58.3)          | 12 (50.0)      |
| Smoking history | 7 (58.3)          | 6 (50.0)          | 13 (54.2)      |
| Atrial fibrillation | 6 (50.0) | 7 (58.3) | 13 (54.2) |
| Stroke          | 0 (0.0)           | 0 (0.0)           | 0 (0.0)        |
| Cognitive impairment | 0 (0.0) | 1 (8.3) | 1 (4.2)   |
| KCCQ overall score | 54.5 (± 20.0) | 58.3 (± 22.8) | 56.4 (± 21.1) |
| KCCQ clinical score | 57.2 (± 22.9) | 66.2 (± 20.3) | 61.7 (± 21.6) |
| Systolic blood pressure | 106.7 (± 16.1) | 114.5 (± 13.9) | 110.6 (± 15.3) |
| Diastolic blood pressure | 66.4 (± 9.0) | 69.5 (± 9.7) | 67.9 (± 9.3) |
| BMI             | 33.2 (± 7.6)      | 33.0 (± 7.7)      | 33.1 (± 7.4)   |
| NT-proBNP, mg/L, median (IQR) | 4664 (144, 26,861) | 2744 (406, 17,945) | 3898 (144, 26,861) |
| Erythrocyte TPP, nmol/L | 186.3 (±45.5) | 169.0 (±30.7) | 177.6 (±39.0) |
| Medications     |                   |                   |                |
| ACEi/ARB/ARNI   | 8 (66.7)          | 11 (91.7)         | 19 (79.2)      |
| β-blocker       | 12 (100.0)        | 12 (100.0)        | 24 (100.0)     |
| Aldosterone antagonist | 4 (33.3) | 8 (66.7) | 12 (50.0) |
| Nitrate         | 0 (0.0)           | 2 (16.7)          | 2 (8.3)        |
| Calcium channel blocker | 1 (8.3) | 0 (0.0) | 1 (4.2) |
| Thiazide        | 1 (8.3)           | 0 (0.0)           | 1 (4.2)        |
| Loop diuretic   | 11 (91.7)         | 8 (66.7)          | 19 (79.2)      |
| Hydralazine     | 0 (0.0)           | 1 (8.3)           | 1 (4.2)        |
| Digoxin         | 0 (0.0)           | 1 (8.3)           | 1 (4.2)        |
| Amiodarone      | 3 (25.0)          | 3 (25.0)          | 6 (25.0)       |
| Acetylsalicylic acid | 3 (25.0) | 2 (16.7) | 5 (20.8) |
| Anticoagulation | 7 (58.3)          | 9 (75.0)          | 16 (66.7)      |
| Multivitamins   | 2 (16.7)          | 1 (8.3)           | 3 (12.5)       |
| Echography      |                   |                   |                |
| LVEF, %         | 34.2 (±8.1)       | 31.9 (±12.8)      | 33.1 (±10.5)   |
| Peak GLS, %     | −7.7 (±3.6)       | −8.6 (±2.3)       | −8.1 (±3.1)    |

Values are n (%), or mean (±standard deviation), unless otherwise indicated. Patients were randomized to starting with thiamine or placebo during the first study phase.

ACEi, angiotensin-converting-enzyme inhibitor; ARB, angiotensin II receptor blocker; ARNI, angiotensin receptor-neprilysin inhibitor; BMI, body mass index; GLS, global longitudinal strain; IQR, interquartile range; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal pro-brain natriuretic peptide; NYHA, New York Heart Association; KCCQ, Kansas City Cardiomyopathy Questionnaire; TPP, thiamine pyrophosphate.
incorporating several timepoints. Statistical analysis was done using SPSS version 26 (IBM, Armonk, NY).

**Results**

**Baseline characteristics**

In the 24 patients enrolled (Table 1), the mean age was 73.4 years (standard deviation [SD] 7.4 years), and 7 were female (29.2%). The baseline NYHA class was II in 18 patients (75.0%), and III in 6 patients (25.0%). The etiology of the HF was ischemic in 16 patients (66.7%). All patients were on a beta blocker; 19 patients (79.2%) were on an angiotensin-converting enzyme inhibitor/angiotensin receptor blocker or angiotensin receptor-neprilysin inhibitor; 12 (50.0%) were on an aldosterone antagonist; and 19 (79.2%) were on a loop diuretic. Only one patient had documented cognitive impairment, and that patient had a caregiver

**Table 2. Feasibility outcomes**

| Measure           | Target            | Observed  | Description                                                                 |
|-------------------|-------------------|-----------|-----------------------------------------------------------------------------|
| Recruitment rate  | 24 patients in 11 months | 24 patients in 21 months | Challenges in recruitment, due to comorbidities, illness severity, no full-time research assistant, COVID-19 |
| Refusal rate      | < 40%             | 37%       | 37 of 100 eligible patients declined to participate                         |
| Retention rate    | > 80%             | 92%       | 2 of 24 patients dropped out for personal reasons                            |
| Adherence rate    | > 90%             | 92.5%     | Participants were adherent to the medication in 37 of 40 study periods. We excluded those who died or dropped out before taking the study drug |

![Figure 1. Consolidated Standards of Reporting Trials (CONSORT) flow diagram.](image-url)
administering medications. HF-related quality of life as measured by mean KCCQ overall score was 56.4 (SD 21.1), which indicates fair-to-good health status.17 Half of the patients (n = 12) had a HF hospitalization in the 12 months prior to enrollment. The median baseline NT-proBNP was 3898 mg/L (interquartile range [IQR] 144-26861 mg/L). The mean LVEF was 33.1% (SD 10.5%), and peak global longitudinal strain was -8.1% (SD 3.1%).

Patients starting on thiamine or placebo (phase 1) were similar in most characteristics (Table 1). There were more female patients in the group starting with thiamine (n = 5 of 12 [41.7%] vs 2 of 12 [16.7%] in the placebo phase 1 group). The NT-proBNP level was also higher in the thiamine-first group, but the IQR was wide and overlapping (4664 mg/L [IQR 144-26,861] vs 2744 mg/L [IQR 406-17,945] in the placebo group). More patients were on a loop diuretic in the thiamine-first group (n = 11 of 12 [91.7%] vs 8 of 12 [66.7%] in the placebo group).

Feasibility outcomes

We screened 330 patients over 21 months to recruit 24 patients (Fig. 1), which did not meet our primary feasibility outcome of recruitment within 11 months (Table 2). Of the 100 patients who met inclusion criteria, 37 declined to participate. Two patients dropped out due to personal reasons, and one died after dropping out. Three other participants died of HF during the study. A total of 19 patients completed the trial. COVID-19 affected our ability to recruit patients, due to restrictions on in-person research. The overall refusal rate was 37% (feasibility threshold < 40%), the retention rate was 92% (feasibility threshold > 80%), and the adherence rate was 92.5% (feasibility threshold > 90%).

Exploratory clinical outcomes

We did not find period or carryover effects between the groups. The mean erythrocyte TPP level increased in the thiamine group but was unchanged in the placebo group (Fig. 2). Comparing thiamine and placebo groups (Table 3), nonsignificant improvements occurred in the thiamine group in mean peak GLS (-8.4% vs -8.0%, P = 0.451), LVEF (39.4% vs 36.7%, P = 0.173), and NT-proBNP level (2805 mg/L vs 3781 mg/L, P = 0.113). Quality of life as measured by mean KCCQ overall score was lower in the thiamine group (60.1 vs 67.0, P = 0.046). When we analyzed the KCCQ clinical score, the difference was not significant (69.3 vs 72.3, P = 0.338). A secondary analysis of only the first study phase (before crossover) showed no differences in all outcomes (Supplemental Table S1). Reasons for missing clinical outcomes mainly included COVID-19 research restrictions and uninterpretable echocardiography images (for GLS), due to study quality (Supplemental Table S2). The mean baseline, 3-month, and within-period changes in outcome measures are shown in Supplemental Table S3. A secondary analysis of LVEF with adjustment for baseline values using a linear mixed-effects model did not reveal differences from pairwise comparisons.

Adverse events

A total of 13 serious adverse events occurred in 7 patients (29.2%); none were related to the study drug (Table 4). A total of 4 deaths (16.7%) occurred over the study period, all related to HF and occurring during both the placebo and thiamine phases. A total of 9 hospitalizations occurred in 5 patients (20.8%). Most of the hospitalizations occurred in the washout or placebo phases, with only 2 occurring in the thiamine phase. Admissions were HF related in 3 patients. Nonserious adverse events occurred in 6 patients (25.0%), with one patient having 2 episodes of atrial fibrillation in both phases of the trial. One patient had diarrhea after starting the study medication—the only adverse event related to the study drug, which resolved after discontinuation of the medication.

Discussion

In this pilot trial of thiamine supplementation in older adults with HFrEF, we were unable to recruit the target number of patients within 11 months, but our other feasibility targets were reached, including retention, refusal, and adherence rates. Similar to a recent parallel group thiamine trial,4 our study did not identify statistically significant benefits of thiamine supplementation, despite using a higher daily dose (500 mg) than previous trials (100-300 mg).7,8,18-20 The use of sensitive markers, such as peak GLS on echocardiography and NT-proBNP level, reveal nonsignificant improvement with supplementation over 3 months.

Our trial was unique because we included older and sicker patients, with lower baseline thiamine levels, compared with those in previous thiamine trials. The mean baseline thiamine level was 178 nmol/L in our trial, whereas the level in other trials3,19 ranged from 216 to 321 nmol/L. Our mean age was 73 years, whereas the other chronic HF thiamine trials8,18-20 had a lower mean age (range: 56.7-69.5 years). HF-related deaths occurred in 16.7% of patients during our 7.5-month trial, whereas HF deaths varied from 0% to 16% in previous trials of up to 6 months in length.7,8,18-20 The inclusion of older patients with more cardiovascular events allowed us to better understand how thiamine impacts this population. Recent publications show that older patients are just as likely...
as younger patients to respond to HF therapy.\textsuperscript{21,22} However, this population also posed challenges to recruitment, as patients were often too sick or frail to participate. This feasibility trial highlights why older adults with multimorbidity are often excluded from HF trials,\textsuperscript{23} which sometimes raises question around the application of evidence to this population.

Biomarkers, including NT-proBNP level, peak GLS, and LVEF, did not differ significantly between groups in our trial, although all 3 outcomes showed a nonsignificant improvement in the thiamine group. In previous studies, one small trial found an improvement in LVEF,\textsuperscript{20} and another trial found an improvement in peripheral edema\textsuperscript{7} with thiamine, but other outcomes were not different. Studies of acute decompensated HF also did not find improvement in LVEF with intravenous thiamine.\textsuperscript{18} Our study revealed a lower HF-related quality-of-life score with thiamine, as measured by the KCCQ overall score. The sample size was small, and the P value was just under 0.05, so the finding may be spurious. A separate analysis of the KCCQ clinical score did not show a significant difference, suggesting that the overall score difference was likely spurious. Looking at the exploratory clinical outcomes from our study in the context of published literature indicates that thiamine supplementation does not consistently improve outcomes in patients with HFREF.

Several lessons gleaned from this pilot trial are applicable to a definitive larger trial. First, recruitment strategies should be improved so that patients outside of the heart-function clinic can be successfully included. Establishing partnerships with local cardiology clinics, in both hospital and external sites, may help reach the recruitment target faster. Second, travel arrangements for trial visits should accommodate the needs of older adults. Many patients needed family or others to drive them to visits, so we arranged and paid for transportation to ensure that patients could attend. Third, the unprecedented research restrictions due to COVID-19 led to missed lab tests and echocardiography. A future trial protocol can consider virtual follow-up for certain visits, and mobile in-home lab tests where possible, which would both improve convenience for patients and mitigate risks due to pandemics.

### Table 3. Exploratory clinical outcomes for thiamine vs placebo

| Outcome                              | Thiamine (n = 24) | Placebo (n = 24) | Mean difference (95% CI)* | P*  |
|--------------------------------------|------------------|-----------------|--------------------------|-----|
| Peak GLS, %                          | 10 (3.4)         | 10 (3.7)        | 0.42 (−0.8, 1.6)         | 0.451 |
| LVEF, %                              | 13 (11.5)        | 13 (12.7)       | −2.8 (−7.0, 1.3)         | 0.173 |
| KCCQ overall score                   | 18 (19.5)        | 16 (19.6)       | −6.8 (13.3, −4.0)        | 0.046 |
| KCCQ clinical score                  | 18 (16.4)        | 16 (16.9)       | −2.9 (−3.3, 9.3)         | 0.338 |
| NYHA class, mean (SD)                | 19 (0.5)         | 16 (0.6)        | 0.1 (−1.7, 0.4)          | 0.414 |
| NYHA class, median (IQR)             | 19 (2.25−2)      | 2 (IQR)         | N/A                      | 0.414 |
| NT-proBNP, mean (SD)                 | 14 (3099.8)      | 3781.1 (4535.9) | −975.8 (−2124.5, 172.7) | 0.113 |
| NT-proBNP, median (IQR)              | 14 (1265.3−3475.0) | 4144.0 (1224.5−4858) | N/A | 0.140 |

*Values are mean (standard deviation), unless otherwise indicated. N-terminal pro-brain natriuretic peptide (NT-proBNP) and New York Heart Association (NYHA) class also compared with Wilcoxon test because of skew (P = 0.140 and P = 0.414, respectively).

GLS, global longitudinal strain; KCCQ, Kansas City Cardiomyopathy Questionnaire (quality of life); LVEF, left ventricular ejection fraction; N/A, not applicable.

\* Paired difference.

\textsuperscript{1} P values for treatment effect from analysis of variance that includes period and carryover effect.

### Table 4. Adverse events by phase of the trial

| Adverse events       | Thiamine phase | Washout phase | Placebo phase | Total\textsuperscript{1} |
|----------------------|---------------|---------------|---------------|--------------------------|
| Serious\textsuperscript{*} | 5 (58.5)      | 3 (23.1)      | 6 (46.2)      | 13 (100.0)               |
| Death                | 2 (50.0)      | 0 (0.0)       | 2 (50.0)      | 4 (100.0)                |
| HF—related death     | 2 (50.0)      | 0 (0.0)       | 2 (50.0)      | 4 (100.0)                |
| Hospitalizations     | 2 (22.2)      | 3 (33.3)      | 4 (44.4)      | 9 (100.0)                |
| HF                   | 0 (0.0)       | 1 (33.3)      | 2 (66.7)      | 3 (100.0)                |
| Pneumonia            | 0 (0.0)       | 0 (0.0)       | 1 (100.0)     | 1 (100.0)                |
| COPD exacerbation    | 0 (0.0)       | 1 (100.0)     | 0 (0.0)       | 1 (100.0)                |
| Hip fracture         | 1 (100.0)     | 0 (0.0)       | 0 (0.0)       | 1 (100.0)                |
| Atrial fibrillation  | 1 (100.0)     | 0 (0.0)       | 0 (0.0)       | 1 (100.0)                |
| Hernia               | 0 (0.0)       | 0 (0.0)       | 1 (100.0)     | 1 (100.0)                |
| AKI                  | 0 (0.0)       | 0 (0.0)       | 1 (100.0)     | 1 (100.0)                |
| Nonsensitive         | 3 (42.9)      | 2 (28.6)      | 2 (28.6)      | 7 (100.0)                |
| Atrial fibrillation  | 1 (50.0)      | 1 (50.0)      | 0 (0.0)       | 2 (100.0)                |
| Nausea/vomiting      | 0 (0.0)       | 0 (0.0)       | 1 (100.0)     | 1 (100.0)                |
| Pneumonia            | 0 (0.0)       | 1 (100.0)     | 0 (0.0)       | 1 (100.0)                |
| Swollen hands        | 0 (0.0)       | 1 (100.0)     | 0 (0.0)       | 1 (100.0)                |
| Back pain            | 1 (100.0)     | 0 (0.0)       | 0 (0.0)       | 1 (100.0)                |
| Diarrhea             | 1 (100.0)     | 0 (0.0)       | 0 (0.0)       | 1 (100.0)                |

\textsuperscript{*} Values are n (%).

\textsuperscript{1} The percentages are calculated by row.

AKI, acute kidney injury; COPD, chronic pulmonary obstructive disease; HF, heart failure.

\* Serious adverse events included hospitalization and death.
Our pilot trial has several limitations. First, we did not meet the primary feasibility threshold, so optimization of the trial recruitment process is needed if a definitive trial is to be done. Second, the crossover design limited interpretation of clinical endpoints, such as death, because patients received both the study drug and placebo sequentially. Third, we included only one patient with cognitive impairment, despite its prevalence in the HF population, which limits generalizability. Fourth, only 79.2% of patients were on a loop diuretic. Thiamine deficiency has been reported to be more common in patients taking loop diuretics, so perhaps this limited the effectiveness of the administered thiamine. We also did not collect data on renal function in our assessments. Fifth, interpretation of LVEF, and to a lesser extent GLS, was dependent on image quality and reader technique. Although we had dedicated cardiologists or echocardiography fellows interpreting the images, we were not able to use consistent technicians or echocardiography machines, due to resource limitations. Sixth, challenges with echocardiographic image quality and test availability during COVID-19 led to missing data for GLS, LVEF, and NT-proBNP level, thereby affecting interpretation of these outcomes.

Our trial also has several strengths. First, we included older adults, the most vulnerable population. Despite challenges with recruitment, we were able to complete the trial with a suitable retention rate. Second, we included HF-related quality of life, a patient-centred outcome. Third, we included a team of cardiologists, geriatricians, and internists in the design and conduct of the trial. This interdisciplinary approach allowed optimization of trial procedures specifically for older adults with HF, including creating a trial drug that could be administered once daily instead of twice daily, ensuring that the capsule could be swallowed easily by older adults, and engaging family and informal caregivers in trial visits. Fourth, we used the highest daily dose of thiamine used in any chronic HF trial, which provides data on tolerability and increases potential effectiveness. Future trials can use a 500-mg daily dose, which was well tolerated in this population.

Conclusion

Based on our pilot trial, high-dose thiamine administration appears well tolerated by older adults with HF. Potential benefits were identified based on biomarker outcomes. Although our recruitment rate was not met, a definitive trial of thiamine supplementation in older adults with HF may be possible if recruitment strategies are enhanced.

Acknowledgements

We thank Accurex Health Care Manufacturing for providing the study medication and placebo in kind; Tanya Reading for technical and logistic support for our study medication; and Gita Sobhi and Diane Lourenco for medication dispensing and storage. We also thank Dr Michael Farkouh for reviewing our safety data.

Funding Sources

This work was funded by the Hamilton Health Sciences New Investigator Fund and supplemental funding from McMaster/St. Peter’s Hospital Chair of Aging. E.K.C.W. was funded by the Vanier Scholarship (Canadian Institutes of Health Research) and the Clinician Scientist Training Program from the University of Toronto. C.D. received funding from Novartis for other research. Sharon Straus was funded by a Tier 1 Canada Research Chair.

Disclosures

The authors have no conflicts of interests to disclose.

References

1. Thomson AD. Mechanisms of vitamin deficiency in chronic alcohol misusers and the development of the Wernicke-Korsakoff syndrome. Alcohol Alcohol Suppl 2000;35:2-7.
2. Hanninen SA, Darling PB, Sole MJ, Barr A, Keith ME. The prevalence of thiamin deficiency in hospitalized patients with congestive heart failure. J Am Coll Cardiol 2006;47:354-61.
3. Neubauer S. The failing heart—an engine out of fuel. N Engl J Med 2007;356:1140-51.
4. Wilkinson TJ, Hanger HC, George PM, Sainsbury R. Is thiamine deficiency in elderly people related to age or co-morbidity? Age Ageing 2000:29:111-6.
5. Rieck J, Halkin H, Almg S, et al. Urinary loss of thiamine is increased by low doses of furosemide in healthy volunteers. J Lab Clin Med 1999;134:238-43.
6. Dinicolantonio JJ, Lave CJ, Niazi AK, O’Keefe JH, Hu T. Effects of thiamine on cardiac function in patients with systolic heart failure: systematic review and metaanalysis of randomized, double-blind, placebo-controlled trials. Ochsner J 2013;13:495-9.
7. Mousavi M, Namazi S, Avadi M, Amirahmadi M, Salehifar D. Thiamine supplementation in patients with chronic heart failure receiving optimum medical treatment. J Cardiol Curr Res 2017:9:00316.
8. Mousavi M, Namazi S, Avadi M, Amirahmadi M, Salehifar D. Thiamine supplementation in patients with chronic heart failure receiving optimum medical treatment. J Cardiol Curr Res 2017:9:00316.
9. Mousavi M, Namazi S, Avadi M, Amirahmadi M, Salehifar D. Thiamine supplementation in patients with chronic heart failure receiving optimum medical treatment. J Cardiol Curr Res 2017:9:00316.
10. Wong EKC, Lee JY, Leong DP, et al. Thiamine versus placebo in older heart failure patients: study protocol for a randomized controlled crossover feasibility trial (THIAMINE-HF). Pilot Feasibility Stud 2018:4:149.
11. McMurray JJV, Krum H, Abraham WT, et al. Aliskiren, enalapril, or aliskiren and enalapril in heart failure. N Engl J Med 2016;374:1521-32.
12. McMurray JJV, Packer M, Desai AS, et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 2014;371:993-1004.
13. Dwan K, Li T, Altman DG, Elbourne D. CONSORT 2010 statement: extension to randomised crossover trials. BMJ 2019;366:l4378.
14. Green CP, Porter CB, Bresnahan DR, Sperrus JA. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure. J Am Coll Cardiol 2000;35:1245-55.
15. Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat 2005;4:287-91.
16. Hertzog MA. Considerations in determining sample size for pilot studies. Res Nurs Health 2008;31:180-91.

17. Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol 2020;76:2379-90.

18. Smithline HA. Thiamine for the treatment of acute decompensated heart failure. Am J Emerg Med 2007;25:124-6.

19. Schoenenberger AW, Schoenenberger-Berzins R, der Maur CA, et al. Thiamine supplementation in symptomatic chronic heart failure: a randomized, double-blind, placebo-controlled, cross-over pilot study. Clin Res Cardiol 2012;101:159-64.

20. Shimon I, Almog S, Vered Z, et al. Improved left ventricular function after thiamine supplementation in patients with congestive heart failure receiving long-term furosemide therapy. Am J Med 1995;98:485-90.

21. Floria VG, Rector TS, Anand IS, Cohn JN. Heart failure with improved ejection fraction: clinical characteristics, correlates of recovery, and survival: results from the Valsartan Heart Failure Trial. Circ Heart Fail 2016;9:e003123.

22. Albakri A. Heart failure with improved ejection fraction: a review and pooled analysis of pathophysiology, diagnosis and clinical management. Rev Artic Intern Med Care 2020;4:2020.

23. Bourgeois FT, Orenstein L, Ballakur S, Mandl KD, Ioannidis JPA. Exclusion of elderly persons in randomized clinical trials of drugs for ischemic heart disease. J Am Geriatr Soc 2017;65:2354.

24. Suter PM, Haller J, Hany A, Vetter W. Diuretic use: a risk for subclinical thiamine deficiency in elderly patients. J Nutr Health Aging 2000;4:69-71.

Supplementary Material

To access the supplementary material accompanying this article, visit CJC Open at https://www.cjcopen.ca/ and at https://doi.org/10.1016/j.cjco.2022.02.007.